Nautilus Biotechnology Launches Early Access Program for Single-Molecule Proteomics Platform with Tau Proteoforms Assay
核心洞察
Nautilus Biotechnology has launched an Early Access Program for its novel single-molecule proteomics platform, featuring a tau proteoforms assay (搜索) as the first offering for exclusive researcher groups.
The platform's Iterative Mapping method enables single-molecule analysis of proteins and proteoforms, designed to achieve comprehensive proteome coverage and precisely map post-translational modifications patterns.
Researchers at the Buck Institute for Research on Aging are successfully using the platform to map up to 768 distinct tau (搜索) proteoforms across brain regions, revealing disease progression patterns.
Nautilus Biotechnology has launched an Early Access Program for its novel single-molecule proteomics platform, marking a significant milestone in the company's path to commercialization. The program debuts with a tau proteoforms assay (搜索) as its first offering, making the company's Iterative Mapping approach available to an exclusive group of researchers.
Revolutionary Single-Molecule Analysis Technology
The Nautilus platform employs an Iterative Mapping method that enables single-molecule analysis of proteins and proteoforms, designed to achieve comprehensive proteome coverage and detail at scale. This technology empowers researchers to precisely map combinatorial patterns of post-translational modifications on individual proteins and study how those patterns evolve during diseases such as Alzheimer's and other neurodegenerative disorders (搜索).
"Through years of validation, we've shown that our platform delivers reproducible, high-quality proteomic data with a level of resolution and scale that differentiates it from other approaches," said Sujal Patel, co-founder and CEO of Nautilus. "These capabilities give us the confidence to launch the Early Access Program, knowing our customers will be set up for success from the outset."
The high level of resolution provided by the platform makes it possible to uncover biological insights that are difficult or impossible to obtain with conventional proteomics approaches such as traditional affinity-based methods and mass spectrometry.
Validated Performance in Alzheimer's Research
The tau proteoforms assay (搜索) demonstrates the strong performance and accessibility of the Nautilus Platform. A Nautilus preprint debuting the assay details the platform's capabilities in analyzing Alzheimer's disease (搜索) brain samples, providing initial validation of its accuracy, sensitivity, dynamic range, and reproducibility for interrogating billions of single-protein molecules at scale.
Independently, researchers at the Buck Institute for Research on Aging are using Nautilus' first externally deployed instrument to map up to 768 distinct tau (搜索) proteoforms across different brain regions. This work has revealed region-specific proteoform patterns associated with disease progression, opening new avenues for studying neurodegenerative biology. The successful adoption by first-time users at the Buck Institute reinforces the platform's accessibility and commercial readiness for research use.
Comprehensive Program Offerings
Beyond standard tau (搜索) assays for Alzheimer's and neurodegenerative research, the Early Access Program offers exclusive development partnerships to support the creation of custom assays tailored to specific research applications. Participants will receive support from Nautilus for guidance on data interpretation, quantification, and analysis, supporting rapid adoption and the generation of actionable biological insights.
The Early Access Program represents a key milestone in Nautilus' path to commercialization, demonstrating the platform's expected readiness for external use as the company advances capabilities in the future, including additional targeted proteoform analyses, broadscale proteomics, and beyond.
Looking Forward
Nautilus will host a webinar titled "Advancing next-generation proteomics with single-molecule Iterative Mapping" on January 14, 2026, at 9:00 AM PT, highlighting the quantitative benefits of Iterative Mapping for proteomics analysis and presenting updated data from the Buck Institute research collaboration.
Researchers interested in gaining early access to the Nautilus platform, either through the standard tau (搜索) assay service or through custom assay development, can learn more at nautilus.bio/nautilusEAP/.